Table 3 The roles of ferroptosis in the treatment of urological malignancies.
From: Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies
Cancer | Drug | Target | Ferroptosis (inducer inhibitor) | Biological function | Model | Reference |
|---|---|---|---|---|---|---|
RCC | KLF2 | Induce | Suppress proliferation, migration and invasion abilities of RCC cells | In vitro and in vivo | [29] | |
AIM2 | Inhibit | Promote RCC progression and sunitinib resistance | In vitro and in vivo | [39] | ||
MLYCD | Induce | Reduce tumor growth and reverse resistance to sunitinib | In vitro and in vivo | [43] | ||
OGT | Induce | Promote the proliferation, clone formation, and invasion of VHL-mutated ccRCC cells | In vitro and in vivo | [48] | ||
Knockdown of SETD2 | Induce | Promote tumor cell death | In vitro and in vivo | [103] | ||
STEAP3 | Inhibit | Poor survival and prognosis | In vitro | [104] | ||
RSL3 or Erastin | Induce | Overcome resistance to everolimus | In vitro | [105] | ||
MIL-101(Fe)@RSL3 | Induce | In vitro and in vivo | [107] | |||
NCOA4 | Induce | Maintain ferritinophagy | In vitro and in vivo | |||
CX3CL1 | Induce | Inhibit tumor cell proliferation and metastasis | In vitro and in vivo | [110] | ||
PCa | Flubendazole | Induce | Inhibit cell proliferation,cause cell cycle arrest in G2/M phase and promoted cell death | In vitro and in vivo | [51] | |
PHGDH | Inhibit | Promote cell growth and Enza resistance in CRPC cells | In vitro and in vivo | [56] | ||
TQB3720 | Induce | Inhibit the growth of prostate cancer | In vitro and in vivo | [59] | ||
AOC1 | Induce | Reduce proliferation and migration in prostate cancer | In vitro and in vivo | [67] | ||
Erastin or RSL3 | Induce | Halt prostate cancer cell growth and migration in vitro and tumor growth in vivo | In vitro and in vivo | [111] | ||
Icariin and curcumol | Induce | Induce autophagy in PCa cells | In vitro and in vivo | [113] | ||
Ferumoxytol | Induce | Enhance NK cells’ function | In vitro and in vivo | [114] | ||
BCa | NCT-502 | PHGDH | Inhibit | Induce tumor progression | In vitro and in vivo | [69] |
EMP1 | Induce | Suppress tumor cell metastasis | In vitro and in vivo | [70] | ||
BQR@MLipo | Induce | Trigger ferroptosis of bladder cancer | In vitro and in vivo | [74] | ||
FLRT2 | Induce | Suppress tumor cell growth, migration and invasion | In vitro | [76] | ||
Abietic acid (AA) | Induce | Selectively inhibited the viability of BC cells | In vitro and in vivo | [78] | ||
RP11-89 | Inhibit | Promote cell proliferation, migration and tumorigenesis and inhibited cell cycle arrest | In vitro and in vivo | [117] | ||
LUCAT1 | Inhibit | Foster cell proliferation, migration, and invasion | In vitro and in vivo | [119] | ||
Evodiamine | Induce | Suppress the migratory ability, decreas the expression of mesenchymal markers, and increase epithelial marker expression | In vitro and in vivo | [120] |
